> PC9919A 121\*241 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## BUCH ET AL SERIAL NO: 09/512,914 FILED: FEBRUARY 25, 2000 FOR: THERAPEUTIC COMBINATION Assistant Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56 AND 1.97 - 1.98

Sir:

As set forth in the Second Supplemental Amendment filed concurrently herewith,
Applicants are submitting an English language counterpart to EP 738510. Applicants are also
enclosing a translation of WO 97/15291 (which corresponds to DE 19539363 A). Applicants
respectfully request that the Examiner consider these references in her examination of the abovereferenced application.

The present Information Disclosure Statement is being filed after three (3) months from the filing date of the above-identified application and after the mailing date of a First Office Action on the merits. Accordingly, Applicants have enclosed a check in the amount of \$180.00 to satisfy the requirements of 37 CFR §1.97 (c) and §1.17 (p).

Should any additional fees be required by this paper, the Commissioner is hereby

authorized to charge any amount which may be required by this paper to the Account of the undersigned attorneys, Deposit Account No. 03-2775.

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ

By: Rufolf Huter

Rudolf E. Hutz Reg. 22,397 Connolly, Bove, Lodge & Hutz

I would M. Olowbe (# 39,794) for

1220 Market Street

P. O. Box 2207

Wilmington, Delaware 19899

(302) 658-9141

enclosures GMO/jab

::ODMA\MHODMA\CB;189849;1